Towards a Privacy Preserving Cohort Discovery Framework for Clinical Research Networks

Conclusions PPCD services can be designed for clinical research networks. The security construction presented in this work specifically achieves high privacy guarantees by preventing both threats originating from within and beyond the network. Graphical abstract
Source: Journal of Biomedical Informatics - Category: Information Technology Source Type: research

Related Links:

Conclusion: If otologic manifestations such as facial palsy and hearing loss are presented in patients at advanced stages of malignancy, TBM of primary malignancy should be suspected. In addition, hematologic malignancies tend to metastasize to the external auditory canal and the middle ear cleft more commonly than solid cancers do. PMID: 29909612 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Otorhinolaryngology - Category: ENT & OMF Tags: Clin Exp Otorhinolaryngol Source Type: research
Juan-Juan Gao, Yang Zhang, Markus Gerhard, Raquel Mejias-Luque, Lian Zhang, Michael Vieth, Jun-Ling Ma, Monther Bajbouj, Stepan Suchanek, Wei-Dong Liu, Kurt Ulm, Michael Quante, Zhe-Xuan Li, Tong Zhou, Roland Schmid, Meinhard Classen, Wen-Qing Li, Wei-Cheng You, Kai-Feng Pan
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
African Americans and Latinos with recent-onset diabetes have a much higher risk of developing pancreatic cancer than their counterparts without diabetes.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Seyeon Park, Seunghyun Ahn, Yujeong Shin, Yoonjung Yang, Chang H. Yeom
Source: Frontiers in Physiology - Category: Physiology Source Type: research
BREAST cancer symptoms begin to appear when cells grow and divide uncontrollably in this area. You should check your whole breast regularly for any warning sign of breast cancer. Watch out for these three signs of the condition.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
ZURICH/LONDON (Reuters) - Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) , raising its bet on the U.S. genomic profiling group's ability to personalize cancer care.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
This review highlights evidence from recent practice-changing clinical trials on new approaches to sentinel lymph node biopsy and axillary lymph node dissection in breast cancer patients.American Journal of Clinical Pathology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
By CHARLES SILVER and DAVID A.HYMAN Today THCB is happy to publish a piece reflecting the learnings from Charles Silver and David Hyman’s forthcoming book Overcharged: Why Americans Pay Too Much For Health Care, shortly to be published by the libertarian leaning Cato Institute. In subsequent weeks we’ll feature commentary from the right (Michael Cannon) and from the left (Andy Slavitt) about the book and its proposals. For now please give your views in the comments–Matthew Holt There are many reasons why the United States is “the most expensive place in the world to get sick.” In Par...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Economics OP-ED Cato Institute Charles Silver David A. Hyman Obamacare Overcharged Source Type: blogs
CONCLUSIONS The present study reveals that in ovarian cancer cells, prucalopride inhibits proliferation, migration, and invasion, and induces apoptosis and autophagy, which may be regulated by the PI3K signaling pathway. These results suggest prucalopride has potential as a new drug for clinical ovarian cancer treatment. PMID: 29909423 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
CONCLUSIONS TCF21 is downregulated in ESCC, and its low expression is closely correlated with N stage and predicts a poor prognosis. TCF21 functions as a tumor suppressor in ESCC progression, and enhancement of its expression levels may be partly through promoting Kiss-1 expression to reverse EMT by modulating EMT-related gene expression. Thus, TCF21 can potentially be used as a treatment target for ESCC. PMID: 29909422 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cervical Cancer | Databases & Libraries | Electronic Health Records (EHR) | Health Insurance | HIPAA | Hysterectomy | Information Technology | Insurance | Mastectomy | Oropharyngeal Cancer | Rare Diseases